Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21306637 | 1.00 | SCN9A (0.50) | SCN9APOLBRAB9ATAS1R3TAS1R1 | |
| SCHEMBL29482010 | 1.00 | SCN9A (0.50) | SCN9APOLBRAB9ATAS1R3TAS1R1 | |
| SCHEMBL20063852 | 0.91 | SCN9A (0.48) | SCN9A | |
| SCHEMBL20072906 | 0.91 | SCN9A (0.48) | SCN9A | |
| SCHEMBL20063765 | 0.91 | SCN9A (0.48) | SCN9A | |
| SCHEMBL20063766 | 0.91 | SCN9A (0.48) | SCN9A | |
| SCHEMBL21296523 | 0.89 | SCN9A (0.42) | SCN9A | |
| SCHEMBL21294888 | 0.89 | SCN9A (0.42) | SCN9A | |
| SCHEMBL21294862 | 0.87 | SCN9A (0.51) | SCN9APOLBRAB9ATAS1R3TAS1R1 | |
| SCHEMBL21294965 | 0.87 | SCN9A (0.43) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | SCN9A 90/4885POLB 4466/4885RAB9A 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.